医学
横纹肌溶解症
前列腺癌
强的松
阿比曲酮
急性肾损伤
雄激素剥夺疗法
肿瘤科
内科学
癌症
泌尿科
雄激素受体
作者
Michael Dineen,Elizabeth Hansen,Elizabeth Ann Guancial,Lynn Sievert,Deepak M. Sahasrabudhe
标识
DOI:10.1177/1078155217701294
摘要
Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI